The effect of MEK (MAPK/ERK Kinase) inhibition in BRAF mutant NSCLC has not been thoroughly investigated and a recent study showed that the combination of a BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) was also effective in treating advanced melanoma [12]. Here, BRAF is linked to melanoma.